中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(6): 1335-1341

Efficacy and safety of lenvatinib combined with sintilimab versus atezolizumab combined with bevacizumab in treatment of unresectable hepatocellular carcinoma

DOI: 10.12449/JCH260615

  • Department of Oncology，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Capital Health Development Research Project (2022-2-2175)

More Information
  • Corresponding author: CHEN Jinglong， chejl6412@sina.com （ORCID： 0000-0003-1640-7115）
  • Received Date: 2025-11-28
  • Accepted Date: 2026-03-02
  • Published Date: 2026-06-25
    Abstract
  •   Objective  To investigate the efficacy and safety of lenvatinib combined with sintilimab versus atezolizumab combined with bevacizumab in patients with unresectable hepatocellular carcinoma （uHCC）， aims to provide real-world evidence for clinical personalized treatment.  Methods  A retrospective analysis was performed for 78 patients with uHCC who were admitted to Beijing Ditan Hospital， Capital Medical University， from January 1， 2023， to May 31， 2025， and according to the treatment modality， they were divided into lenvatinib+sintilimab group （L+S group with 49 patients） and atezolizumab+bevacizumab group （A+T group with 29 patients）. The primary endpoints were progression-free survival （PFS） and overall survival （OS）， and the secondary endpoints included objective response rate （ORR）， disease control rate （DCR）， and the incidence rate of adverse events. The independent-samples t test was used for comparison of normally distributed continuous data between groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups； the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used for survival analysis， and the log-rank test was used for comparison between groups.  Results  The 78 patients had a median PFS of 9 months and a median OS of 15 months. The median PFS was 11 months in the L+S group and 7 months in the A+T group， with no significant difference between the two groups （χ2=0.247， P=0.619）； the median OS was 19 months in the L+S group and 12 months in the A+T group， with a significant difference between the two groups （χ2=6.565， P=0.010）. There were no significant differences between the two groups in complete remission， partial remission， stable disease， disease progression， DCR， and ORR （all P>0.05）. The L+S group had a significantly higher incidence rate of adverse events than the A+T group （95.9% vs 75.9%， P=0.007）， and there was a significant difference in the incidence rate of grade ≥3 adverse events between the L+S group and the A+T group （65.3% vs 34.5%， P=0.008）.  Conclusion  Compared with atezolizumab combined with bevacizumab， lenvatinib combined with sintilimab can improve the OS of patients with uHCC， while atezolizumab combined with bevacizumab has a better safety profile.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [2]
    YOUNOSSI ZM, WONG G, ANSTEE QM, et al. The global burden of liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21( 8): 1978- 1991. DOI: 10.1016/j.cgh.2023.04.015.
    [3]
    FAN R, CHEN L, ZHAO SR, et al. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures[J]. J Hepatol, 2023, 79( 4): 933- 944. DOI: 10.1016/j.jhep.2023.05.039.
    [4]
    ZENG HM, CAO MM, XIA CF, et al. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: A multicenter prospective study[J]. Nat Cancer, 2023, 4( 9): 1382- 1394. DOI: 10.1038/s43018-023-00618-8.
    [5]
    KUDO M, FINN RS, QIN SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391( 10126): 1163- 1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [6]
    FINN RS, IKEDA M, ZHU AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38( 26): 2960- 2970. DOI: 10.1200/JCO.20.00808.
    [7]
    LLOVET JM, KUDO M, MERLE P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma(LEAP-002): A randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24( 12): 1399- 1410. DOI: 10.1016/S1470-2045(23)00469-2.
    [8]
    KUDO M, IKEDA M, MOTOMURA K, et al. A phase Ib study of lenvatinib(LEN) plus nivolumab(NIV) in patients(pts) with unresectable hepatocellular carcinoma(uHCC): Study 117[J]. J Clin Oncol, 2020, 38( 4_suppl): 513. DOI: 10.1200/jco.2020.38.4_suppl.513.
    [9]
    SUN W, DING XY, CHEN JL. Efficacy and safety of anti-PD-1 monoclonal antibody combined with sorafenib or lenvatinib in treatment of patients with Child-Pugh class B unresectable hepatocellular carcinoma[J]. J Clin Hepatol, 2024, 40( 5): 975- 981. DOI: 10.12449/JCH240517.

    孙巍, 丁晓燕, 陈京龙. 程序性死亡受体1(PD-1)单抗联合索拉非尼或仑伐替尼治疗肝功能Child-Pugh B级不可切除肝癌患者的效果分析[J]. 临床肝胆病杂志, 2024, 40( 5): 975- 981. DOI: 10.12449/JCH240517.
    [10]
    CAI MY, HUANG WS, LIANG W, et al. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study[J]. Liver Int, 2024, 44( 4): 920- 930. DOI: 10.1111/liv.15831.
    [11]
    FINN RS, QIN SK, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382( 20): 1894- 1905. DOI: 10.1056/NEJMoa1915745.
    [12]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [13]
    LENCIONI R, LLOVET JM. Modified RECIST(mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30( 1): 52- 60. DOI: 10.1055/s-0030-1247132.
    [14]
    U.S. Department of Health& Human Services. CTCAE5.0[EB/OL]. https://ctep.cancer.gov/protocoldevelopment/electronicapplications/ctc.htm. https://ctep.cancer.gov/protocoldevelopment/electronicapplications/ctc.htm
    [15]
    de CASTRIA TB, KHALIL DN, HARDING JJ, et al. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma[J]. Future Oncol, 2022, 18( 33): 3769- 3782. DOI: 10.2217/fon-2022-0652.
    [16]
    ZHU MY, LIU ZL, CHEN SL, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study[J]. Hepatology, 2024, 80( 4): 807- 815. DOI: 10.1097/HEP.0000000000000776.
    [17]
    CASADEI-GARDINI A, RIMINI M, TADA T, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real-life worldwide population[J]. Eur J Cancer, 2023, 180: 9- 20. DOI: 10.1016/j.ejca.2022.11.017.
    [18]
    VITIELLO F, TADA T, SUDA G, et al. Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B(BCLC-B) hepatocellular carcinoma(HCC): A real-world population[J]. Semin Oncol, 2025, 52( 4): 152348. DOI: 10.1016/j.seminoncol.2025.152348.
    [19]
    REMITHA NPSI, DEWI NPRP, KUSUMA IKWA, et al. Efficacy and safety of lenvatinib versus atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma: A systematic review and meta-analysis[J]. Asian Pac J Cancer Prev, 2025, 26( 5): 1529- 1542. DOI: 10.31557/APJCP.2025.26.5.1529.
    [20]
    KIM HD, PARK YG, HONG H, et al. Atezolizumab plus bevacizumab is associated with favorable overall survival over lenvatinib in patients with unresectable hepatocellular carcinoma[J]. Oncology, 2026, 104( 1): 40- 50. DOI: 10.1159/000545351.
    [21]
    LEE MS, RYOO BY, HSU CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140): An open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21( 6): 808- 820. DOI: 10.1016/S1470-2045(20)30156-X.
    [22]
    TOHYAMA O, MATSUI J, KODAMA K, et al. Antitumor activity of lenvatinib(E7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models[J]. J Thyroid Res, 2014, 2014: 638747. DOI: 10.1155/2014/638747.
    [23]
    ZHU YJ, WANG MM, ZHAO SJ, et al. Determination of the earliest time point for efficacy evaluation of transarterial chemoembolization combined with lenvatinib in patients with unresectable hepatocellular carcinoma based on imaging evaluation methods[J]. Clin J Med Offic, 2024, 52( 11): 1123- 1128. DOI: 10.16680/j.1671-3826.2024.11.05.

    祝叶静, 汪檬檬, 赵首捷, 等. 基于影像学评价手段确定经肝动脉化疗栓塞术联合仑伐替尼治疗不可切除肝细胞癌患者疗效评估最早时间节点[J]. 临床军医杂志, 2024, 52( 11): 1123- 1128. DOI: 10.16680/j.1671-3826.2024.11.05.
    [24]
    ADACHI Y, KAMIYAMA H, ICHIKAWA K, et al. Inhibition of FGFR reactivates IFNγ signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies[J]. Cancer Res, 2022, 82( 2): 292- 306. DOI: 10.1158/0008-5472.CAN-20-2426.
    [25]
    KATO Y. Lenvatinib enhances antitumor immunity of anti-PD-1 antibody[J]. Int J Clin Oncol, 2025, 30( 4): 666- 673. DOI: 10.1007/s10147-025-02721-5.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (44) PDF downloads(16) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return